Driving Treg Cell Therapy Innovation via T-Cell Targeting, Multi-Editing, and In Vivo Antigen Specific Tregs

• Overview of PolTREG and Immuthera clinical Treg modalities including “totality of T1D” approach
• T-cell targeting with the novel CD6/CTLA4 CAR-Treg
• In vivo antigen specific Tregs – clinically sourced tolerogenic peptides from 12 year sera samples of T1D patients

Speakers:

Daniel Shelly

Chief Business Development Officer

PolTREG